These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 9711978)

  • 1. Neostriatal mechanisms in Parkinson's disease.
    Chase TN; Oh JD; Blanchet PJ
    Neurology; 1998 Aug; 51(2 Suppl 2):S30-5. PubMed ID: 9711978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine.
    Chase TN
    Neurology; 1998 May; 50(5 Suppl 5):S17-25. PubMed ID: 9591518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synaptic dysfunction in Parkinson's disease.
    Picconi B; Piccoli G; Calabresi P
    Adv Exp Med Biol; 2012; 970():553-72. PubMed ID: 22351072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.
    Chase TN; Oh JD
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S122-9; discussion S129-30. PubMed ID: 10762139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism.
    Chase TN; Oh JD
    Trends Neurosci; 2000 Oct; 23(10 Suppl):S86-91. PubMed ID: 11052225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease.
    Oh JD; Chase TN
    Amino Acids; 2002; 23(1-3):133-9. PubMed ID: 12373527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats.
    Marin C; Jimenez A; Bonastre M; Chase TN; Tolosa E
    Synapse; 2000 Jun; 36(4):267-74. PubMed ID: 10819904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopaminergic modulation of striatal function and Parkinson's disease.
    Zhai S; Shen W; Graves SM; Surmeier DJ
    J Neural Transm (Vienna); 2019 Apr; 126(4):411-422. PubMed ID: 30937538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32.
    Dunah AW; Sirianni AC; Fienberg AA; Bastia E; Schwarzschild MA; Standaert DG
    Mol Pharmacol; 2004 Jan; 65(1):121-9. PubMed ID: 14722243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms.
    Chase TN; Oh JD; Konitsiotis S
    J Neurol; 2000 Apr; 247 Suppl 2():II36-42. PubMed ID: 10991664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synaptic dysfunction in Parkinson's disease.
    Bagetta V; Ghiglieri V; Sgobio C; Calabresi P; Picconi B
    Biochem Soc Trans; 2010 Apr; 38(2):493-7. PubMed ID: 20298209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in nigral NMDA and GABAA receptor control of the striatal dopamine level after repetitive exposures to nitrogen narcosis.
    Lavoute C; Weiss M; Rostain JC
    Exp Neurol; 2008 Jul; 212(1):63-70. PubMed ID: 18452916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal plasticity and extrapyramidal motor dysfunction.
    Chase TN
    Parkinsonism Relat Disord; 2004 Jul; 10(5):305-13. PubMed ID: 15196510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Striatal glutamate induces retrograde excitotoxicity and neuronal degeneration of intralaminar thalamic nuclei: their potential relevance for Parkinson's disease.
    Morales I; Sabate M; Rodriguez M
    Eur J Neurosci; 2013 Jul; 38(1):2172-82. PubMed ID: 23565852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
    Nash JE; Brotchie JM
    Mov Disord; 2002 May; 17(3):455-66. PubMed ID: 12112191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of Striatal N-Methyl-D-Aspartate Receptor (NMDAR) Function by Phosphorylation of its Subunits in Parkinsonian Rats.
    Oh JD
    Methods Mol Med; 2001; 62():247-53. PubMed ID: 21318780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.
    Boileau I; Guttman M; Rusjan P; Adams JR; Houle S; Tong J; Hornykiewicz O; Furukawa Y; Wilson AA; Kapur S; Kish SJ
    Brain; 2009 May; 132(Pt 5):1366-75. PubMed ID: 19153147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motor response complications and the function of striatal efferent systems.
    Chase TN; Mouradian MM; Engber TM
    Neurology; 1993 Dec; 43(12 Suppl 6):S23-7. PubMed ID: 8264907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa-associated motor complications.
    Mouradian MM; Chase TN
    Exp Neurol; 1997 Mar; 144(1):51-7. PubMed ID: 9126152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.